CA2016181A1 - Arylthiazolylimidazoles comme antagonistes du 5ht3 - Google Patents

Arylthiazolylimidazoles comme antagonistes du 5ht3

Info

Publication number
CA2016181A1
CA2016181A1 CA2016181A CA2016181A CA2016181A1 CA 2016181 A1 CA2016181 A1 CA 2016181A1 CA 2016181 A CA2016181 A CA 2016181A CA 2016181 A CA2016181 A CA 2016181A CA 2016181 A1 CA2016181 A1 CA 2016181A1
Authority
CA
Canada
Prior art keywords
arylthiazolylimidazoles
antagonists
het
mono
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2016181A
Other languages
English (en)
Other versions
CA2016181C (fr
Inventor
Arthur A. Nagel
Terry J. Rosen
James P. Rizzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of CA2016181A1 publication Critical patent/CA2016181A1/fr
Application granted granted Critical
Publication of CA2016181C publication Critical patent/CA2016181C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA002016181A 1989-05-09 1990-05-07 Arylthiazolylimidazoles comme antagonistes du 5ht3 Expired - Fee Related CA2016181C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US349,278 1989-05-09
US07/349,278 US4914207A (en) 1989-05-09 1989-05-09 Arylthiazolylimidazoles

Publications (2)

Publication Number Publication Date
CA2016181A1 true CA2016181A1 (fr) 1990-11-09
CA2016181C CA2016181C (fr) 1999-03-23

Family

ID=23371665

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002016181A Expired - Fee Related CA2016181C (fr) 1989-05-09 1990-05-07 Arylthiazolylimidazoles comme antagonistes du 5ht3

Country Status (10)

Country Link
US (1) US4914207A (fr)
EP (1) EP0397365B1 (fr)
JP (1) JPH0692404B2 (fr)
AT (1) ATE102197T1 (fr)
CA (1) CA2016181C (fr)
DE (1) DE69006907T2 (fr)
DK (1) DK0397365T3 (fr)
ES (1) ES2062354T3 (fr)
FI (1) FI94639C (fr)
IE (1) IE62936B1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140034A (en) * 1989-03-14 1992-08-18 Merck Sharp & Dohme Ltd. Five-membered ring systems with bonded imidazolyl ring substituents
JPH07121917B2 (ja) * 1989-07-31 1995-12-25 四国化成工業株式会社 ４（５）―チオカルバモイル―イミダゾール化合物及びその合成方法
WO1992016527A1 (fr) * 1991-03-22 1992-10-01 Nippon Soda Co., Ltd. Derive de pyridine substitue en position 2, sa production, et bactericide d'agrohorticulture
TW294595B (fr) * 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
WO1995024406A1 (fr) * 1994-03-10 1995-09-14 Yamanouchi Pharmaceutical Co., Ltd. NOUVEAU DERIVE de 2-(IMIDAZOLYLMETHYL)THIAZOLE ET COMPOSITION MEDICALE ISSUE DE CE DERIVE
US5874452A (en) * 1996-04-03 1999-02-23 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
EP1003374A4 (fr) * 1996-12-30 2000-05-31 Merck & Co Inc Inhibiteurs de farnesyl-proteine transferase
US6093737A (en) * 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6127390A (en) * 1997-10-02 2000-10-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6426356B1 (en) 1998-11-18 2002-07-30 Ortho-Mcneil Pharmaceutical, Inc. Imidazoethyl thiophenes
HU228783B1 (en) * 2001-07-26 2013-05-28 Greenearth Cleaning Dry cleaning apparatus and method capable of utilizing a siloxane solvent
KR20050033070A (ko) 2002-08-09 2005-04-08 아스트라제네카 에이비이 메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸
JP2010506916A (ja) * 2006-10-20 2010-03-04 メルク エンド カムパニー インコーポレーテッド ボンベシンレセプターサブタイプ３モジュレーターとしての置換イミダゾール
EP2253316B1 (fr) 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur 5-HT3 de la sérotonine pour une utilisation dans le traitement ou la prévention d'une pathologie de l'oreille interne avec déficits vestibulaires
JP5955767B2 (ja) 2009-05-20 2016-07-20 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 損傷性前庭障害の処置における使用のためのセロトニン５−ｈｔ３受容体拮抗薬
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2019033201A1 (fr) 2017-08-14 2019-02-21 Gestion Claude Boivin Inc. Système de bras mécanique destiné à collecter des ordures à partir d'un contenant à ordures

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3519637A (en) 1966-12-06 1970-07-07 Hoffmann La Roche 1-(4-thiazolylmethyl)nitroimidazole derivatives
NL7017486A (fr) * 1969-12-15 1971-06-17
DE1964995A1 (de) * 1969-12-24 1971-07-01 Bayer Ag N-Benzyltriazole,Verfahren zu ihrer Herstellung und ihre Verwendung zur Regulierung des Pflanzenwachstums
US4468399A (en) * 1981-12-28 1984-08-28 Eli Lilly And Company 2-[2-(2-Aminoalkyl-4-thiazolylmethylthio)alkyl]-amino-5-substituted-4-pyrimidones
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
US4746669A (en) 1985-12-23 1988-05-24 Merck & Co., Inc. Substituted thiazoles as immunoregulants
JPH0725754B2 (ja) * 1986-01-30 1995-03-22 富山化学工業株式会社 新規なチアゾール化合物またはその塩
DE3830240A1 (de) * 1987-10-14 1989-04-27 Bayer Ag Substituierte 1-aryl-1-(thiazol-2-yl)-2-(1,2,4-triazol-1-yl)- und -(imidazol-1-yl)-ethanole, verfahren sowie substituierte 1-aryl-1-(thiazol-2-yl)-2-bromethanole als zwischenprodukte zu ihrer herstellung, und sie enthaltende fungizide und pflanzenwuchsregulierende mittel

Also Published As

Publication number Publication date
FI94639B (fi) 1995-06-30
ES2062354T3 (es) 1994-12-16
ATE102197T1 (de) 1994-03-15
JPH032180A (ja) 1991-01-08
EP0397365B1 (fr) 1994-03-02
DE69006907D1 (de) 1994-04-07
CA2016181C (fr) 1999-03-23
JPH0692404B2 (ja) 1994-11-16
DK0397365T3 (da) 1994-05-24
IE901665L (en) 1990-11-09
US4914207A (en) 1990-04-03
EP0397365A1 (fr) 1990-11-14
IE62936B1 (en) 1995-03-08
DE69006907T2 (de) 1994-06-09
FI94639C (fi) 1995-10-10
FI902292A0 (fi) 1990-05-08

Similar Documents

Publication Publication Date Title
CA2016181A1 (fr) Arylthiazolylimidazoles comme antagonistes du 5ht3
FI902661A0 (fi) Menetelmä angiotensiini-II-antagonisteina aktiivisten 3-(2'-(substituoitu)bifen-4-yyli)metyyli-3H-imidatso/4,5-b/pyridiiniyhdisteiden valmistamiseksi
NO913785D0 (no) Fremgangsmaate for fremstilling av fibrinogenreseptorantagonister.
CA2086434A1 (fr) Derives quinuclidine
BG101112A (bg) Използване на хетероциклени съединения
NO895086L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
NO912411D0 (no) Fremgangsmaate for fremstilling av bicykliske heterocykliske forbindelser.
AU1532492A (en) Use of heterocyclic compounds for the treatment of inflammatory pain
FI981709L (fi) Menetelmä 5-substituoitujen 2-amino-4-okso-pyrrolo/2,3-d/-pyrimidiinien valmistamiseksi
IL104706A0 (en) 3-(1h-tetrazol-5-yl)-4h-pyrido(1,2-a)pyrimidine-4-ones and process for the preparation thereof
NO171412C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksatiolan- eller 1,3-ditiolanderivater
ATE171949T1 (de) Neue endothelin-antagonisten und ihre herstellung
MY105555A (en) Heterocyclicguanidines as 5ht 3 antagonists.
RU93005302A (ru) 5,6-дизамещенные-3-пиридилметиламмонийгалоидные соединения, применяемые для получения 5-(замещенный метил)-2,3-пиридинкарбоновых кислот
TR27833A (tr) Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.
BG97059A (bg) Имидазо (4,5-с) пиридини, антагонисти на раf
ATE209633T1 (de) Pyridinderivate,als arzneimittel zur behandlung von geschwüren und als antibakterielle mittel
ATE122044T1 (de) Pyrrolo(1,2-a>imidazol- und imidazo(1,2- a>pyridinderivate und ihre anwendung als 5- lipoxygenase inhibitoren.
FI940607A0 (fi) Imidatso(5,1-C)(1,4)bentsoksatsin-1-onijohdannaiset 5HT3-antagonisteina
NO158675C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive morfantridin-derivater.
FI963808L (fi) Menetelmä (1H-tetratsol-5-yyli)tetratsolo(1,5-a)kinoliinien ja naftyridiinien valmistamiseksi
DE69006745D1 (de) Muscarin-rezeptor-antagonisten.
NO890247D0 (no) Fremgangsmaate for fremstilling av 3-(3-pyridyl)-1h, 3h-pyrrolo-(1,2-c)tiazol-7-karbonitril.
AT388731B (de) Neue derivate von benzimidazol, ihre herstellung und verwendung
NO166128C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazo(1,2-a)pyridinderivater.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed